その他の医薬技術 (JP Patent Analysis Report)
The Theme Code "その他の医薬技術" had 73 patent application filings in the most recent period (2023-01-01 to 2023-03-31). This is a significantly decreased of -945 filings (-92.8%) over 1,018 they had in the same period of the previous year (2022-01-01 to 2022-03-31).
The highest number of filings in 2017 with 6,272 cases, and their lowest number in 2022 with 3,849 cases.
The mean of the number of filings over the last 5 years (2018 to 2023, 25,065 cases in total) is 4,178, and the median is 4,612. The coefficient of variation (standard deviation/mean) is 0.5, and there have been big fluctuations in the number of filings from year to year.
| Index | Value |
|---|---|
| Average | 4,178 patents |
| Std Dev | 1,930 |
| COV | 0.5 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 3,849 cases | -16.31 % |
| 2021 year | 4,599 cases | -0.58 % |
| 2020 year | 4,626 cases | -20.95 % |
This report provides the latest patent analysis information (the IP landscape, including a patent map) on the patent search results of the JP patent database for その他の医薬技術[4C084] for the period of the last 10 years (2014-01-01 to 2024-11-30). You can compare the information in this report with the trends in your competitors’ patent filings and technologies, and use it to search for important patents.
This service provides, free of charge, a patent analysis report based on the latest patent data (Japanese, U.S., European, and PCT application publications) for use in patent searches, patent analysis, and IP landscaping. The service is offered by "Patent Integration" a firm specializing in patent search/patent analysis.
This report includes basic information to help you understand the IP strategy and management of その他の医薬技術, such as changes in the number of patents/patent applications they have filed, comparisons of the numbers of patents/patent applications filed by their peers and competitors, their top coapplicants (joint research partners, alliance partners), and their most important patents. It can be used in various intellectual property business operations such as IP landscaping, patent search/patent analysis, preparation of intellectual property business evaluation reports, selection of M&A candidates, and selection of alliance partners.
- Table of Contents
- Foreign Patent Analysis Report
- Patent Filing Summary for その他の医薬技術
- Search Set (Search Formula/Analysis Patents)
- Related Patent Analysis Report
- Competitors Information
- Top company Information
- • Information on Important Patents
- Provision of patent information to the media
- About this Site
He is a patent attorney at a patent office. He specializes in invention counseling, patent filing, and intellectual property strategies for start-up companies and new businesses in the fields of software, information technology and artificial intelligence. He runs a patent course for beginners on Udemy, an online course provider.
After studying physics at the University of Tokyo as a doctoral student, he was engaged in intellectual property analysis and technology trend research as an in-house patent attorney at a precision equipment manufacturer and at Toyota Central R&D Labs. Inc..
Introduction
The concept of the "IP landscape" (IPL) has been attracting attention recently.
An IP landscape is not limited to patent information, but also integrates and analyzes business information (e.g., non-patent information such as papers, news releases, stock information, and market information). Intellectual-property-based business management is realized through the analysis of intellectual property information applied to the formulation of management strategies and business strategies. This is a comprehensive approach that includes but not limited to planning of open and closed strategies, selecting M&A candidates, searching for alliance partners, and formulating intellectual property strategies, through the exploitation of intellectual property information.
IP landscaping usually includes patent search and patent analysis. In patent search and patent analysis, it is important to grasp the market position of each company and the overall technological trends and development trends for each technology. More specifically, it is important to understand what intellectual property your own company and other companies hold, what the strengths and weaknesses of other companies are, and how other companies are trying to exploit their intellectual property. In other words, it is important to understand both the business strategy and the intellectual property strategy of each company.
After reading this search report, you may be interested in more detailed patent searches and patent analysis. We offer a service called Patent Integration, which is an integrated patent search and patent analysis service. With reasonable pricing and a simple user interface such that even beginners can quickly search for and analyze patent information by company or technology from a web browser, please consider using it for detailed patent searches, patent analysis, and IP landscaping.
Patent Integration has a patent-landscaping function that can visually represent a set of tens of thousands of patents/patent applications. This allows you to convincingly show the technical positions of your company and its competitors to your management and business strategists in order to formulate management strategies and business strategies.
その他の医薬技術, Changes in the Number of JP Patents/Patent Applications
The changes in the number of patent filings of その他の医薬技術 over the last 20 years (JP) are shown below.
The change in the number of patents/patent applications is the most basic index in patent analysis. By examining the change in the number of patents/patent applications, you can see the status of technological development and R&D focus for each company or technology. It should be noted that since there is a one and a half year lag between the filing and the laying open of patent applications, it is not possible to analyze the situation more recently than one and half years prior to the present.
In this report, you can only see the change in the number of patents/patent applications by company or technology, whereas Patent Integration allows you to quickly compare the number of patent applications with your competitors in each technical field by cross-referencing with other keywords and patent classifications.
Patent Landscape ({{ld.d.db_name | country_map: 'en'}})
Patent landscaping is a visualization of the distribution of patent filings (application focus areas) for each technical keyword. Mountains and islands indicated by heatmap contours represent clusters of patent applications filed, and red areas on the heatmap indicate many patent filings relating to the keyword.
The patent landscape for その他の医薬技術 gives an intuitive understanding of what patent filings they have made and what technical position is to be established. By selecting filing year checkboxes and filtering, you can track their past filing trends (what technical area they have focused on).
By selecting applicant/patent holder checkboxes and filtering, you can visually grasp the technical areas of the filings for each applicant and the partnerships or alliances formed. Please use it as a guide for patent analysis and IP landscaping.
In addition, by visually representing the patent data in this manner, you can convincingly show the technical positions of your company and its competitors to your management and business strategists in order to formulate management strategies and business strategies.
In Patent Integration, you can check the specifics of a patent filing by clicking anywhere on the patent landscape screen. You can also quickly check the position of each applicant for each technical field by cross-referencing with other keywords and patent classifications. You can use it as a guide when considering hypotheses about each company's IP strategy on the IP Landscape. You can also use it for higher-grade intellectual property activities. It has reasonable pricing and a simple user interface that is easy for beginners to handle.
Characteristic Terms (Importance)
The following is a list of words (characteristic terms) often used in その他の医薬技術 patent applications. Characteristic terms with a higher importance are used in more patents/patent applications.
Search Set (Analysis Patents)
This patent analysis report was created for a patent search set of 48,663 cases retrieved by applying the following search formula and analysis period to the following patent database. Patent information such as a patent analysis result, a patent map, and a patent landscape can be freely used for patent searches, analysis, and work on intellectual property strategies, including IP landscaping.
その他の医薬技術[4C084]
Same industry / competition company information (JP)
The patent information of the higher applicant in the technical theme その他の医薬技術 is shown below. By comparing the number of patents of each company, you can check the research and development status of each company's past and present technical themes and the position of each company in the technical theme.
Trends in filing of joint patent applications in the last 3 years (2022 to 2024).
Comparing the number of applications of each company, ジェネンテックインコーポレイテッド has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 38 cases, followed by ノバルティスアーゲー with 36 cases.
| Name | Cases |
|---|---|
| ジェネンテックインコーポレイテッド | 38 cases |
| ノバルティスアーゲー | 36 cases |
| ザリージェンツオブザユニバーシティオブカリフォルニア | 25 cases |
| ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 16 cases |
| ブリストル-マイヤーズスクイブカンパニー | 14 cases |
| アムジエン・インコーポレーテツド | 13 cases |
| 武田薬品工業株式会社 | 11 cases |
| エフホフマン-ラロシュアーゲー | 9 cases |
| グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 2 cases |
Trends in filing of joint patent applications for the target period (2014 to 2024).
Comparing the number of applications of each company, ノバルティスアーゲー has the highest number of joint applications in the last for the target period (2014 to 2024) with 747 cases, followed by ジェネンテックインコーポレイテッド with 547 cases.
| Name | Cases |
|---|---|
| ノバルティスアーゲー | 747 cases |
| ジェネンテックインコーポレイテッド | 547 cases |
| ザリージェンツオブザユニバーシティオブカリフォルニア | 421 cases |
| ブリストル-マイヤーズスクイブカンパニー | 274 cases |
| 武田薬品工業株式会社 | 214 cases |
| ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 212 cases |
| エフホフマン-ラロシュアーゲー | 210 cases |
| アムジエン・インコーポレーテツド | 206 cases |
| メルク・シャープ・アンド・ドーム・コーポレーション | 99 cases |
| グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 11 cases |
| メルク・シャープ・エンド・ドーム・コーポレイション | 1 cases |
Same industry / competition company, Change in the Number of JP Patents
Below is a patent map showing changes in the number of applications for JP patents of 11 companies in the same industry over the past 20 years.
Top company information (JP)
The patent information of the higher applicant in the technical theme その他の医薬技術 is shown below. By comparing the number of patents of each company, you can check the research and development status of each company's past and present technical themes and the position of each company in the technical theme.
Trends in filing of joint patent applications in the last 3 years (2022 to 2024).
among the top coapplicants, ジェネンテックインコーポレイテッド has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 38 cases, followed by ノバルティスアーゲー with 36 cases.
| Name | Cases |
|---|---|
| ジェネンテックインコーポレイテッド | 38 cases |
| ノバルティスアーゲー | 36 cases |
| ザリージェンツオブザユニバーシティオブカリフォルニア | 25 cases |
| ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 16 cases |
| ブリストル-マイヤーズスクイブカンパニー | 14 cases |
| 武田薬品工業株式会社 | 11 cases |
Trends in filing of joint patent applications for the target period (2014 to 2024).
among the top coapplicants, ノバルティスアーゲー has the highest number of joint applications in the last for the target period (2014 to 2024) with 747 cases, followed by ジェネンテックインコーポレイテッド with 547 cases.
| Name | Cases |
|---|---|
| ノバルティスアーゲー | 747 cases |
| ジェネンテックインコーポレイテッド | 547 cases |
| ザリージェンツオブザユニバーシティオブカリフォルニア | 421 cases |
| ブリストル-マイヤーズスクイブカンパニー | 274 cases |
| 武田薬品工業株式会社 | 214 cases |
| ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 212 cases |
| メルク・シャープ・アンド・ドーム・コーポレーション | 99 cases |
Top company, Change in the Number of JP Patents
Below is a ranking of the number of JP patent applications by その他の医薬技術’s top 7 coapplicants over the last 20 years.
Below is a patent map showing the changes in the numbers of JP patent filings by その他の医薬技術’s top 7 coapplicants over the last 20 years.
Top company Details (JP)
Trends in filing of joint patent applications with ノバルティスアーゲー
その他の医薬技術 filed 747 joint applications with ノバルティスアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 336 cases in total) is 56.0, and the median is 52.5. The coefficient of variation (standard deviation/mean) is 0.6, and there have been relatively large fluctuations in the number of filings from year to year.
The highest number of filings in 2014 with 119 cases, and their lowest number in 2022 with 35 cases.
| Index | Value |
|---|---|
| Average | 56.0 patents |
| Std Dev | 35.1 |
| COV | 0.6 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 35 cases | -12.50 % |
| 2021 year | 40 cases | -38.5 % |
| 2020 year | 65 cases | -26.97 % |
Trends in filing of joint patent applications with ジェネンテックインコーポレイテッド
その他の医薬技術 filed 547 joint applications with ジェネンテックインコーポレイテッド for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 184 cases in total) is 30.7, and the median is 38.0. The coefficient of variation (standard deviation/mean) is 0.5, and there have been big fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2015 with 117 cases, and their lowest number in 2020 with 28 cases.
| Index | Value |
|---|---|
| Average | 30.7 patents |
| Std Dev | 14.3 |
| COV | 0.5 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 38 cases | -5.00 % |
| 2021 year | 40 cases | +42.9 % |
| 2020 year | 28 cases | -26.32 % |
Trends in filing of joint patent applications with 武田薬品工業株式会社
その他の医薬技術 filed 214 joint applications with 武田薬品工業株式会社 for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 116 cases in total) is 19.3, and the median is 20.0. The coefficient of variation (standard deviation/mean) is 0.6, and there have been relatively large fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2017 with 38 cases, and their lowest number in 2022 with 11 cases.
| Index | Value |
|---|---|
| Average | 19.3 patents |
| Std Dev | 11.6 |
| COV | 0.6 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 11 cases | -50.0 % |
| 2021 year | 22 cases | +22.22 % |
| 2020 year | 18 cases | -40.0 % |
Trends in filing of joint patent applications with ザリージェンツオブザユニバーシティオブカリフォルニア
その他の医薬技術 filed 421 joint applications with ザリージェンツオブザユニバーシティオブカリフォルニア for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 229 cases in total) is 38.2, and the median is 41.0. The coefficient of variation (standard deviation/mean) is 0.6, and there have been big fluctuations in the number of filings from year to year.
The highest number of filings in 2018 with 74 cases, and their lowest number in 2022 with 25 cases.
| Index | Value |
|---|---|
| Average | 38.2 patents |
| Std Dev | 22.5 |
| COV | 0.6 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 25 cases | -34.2 % |
| 2021 year | 38 cases | -13.64 % |
| 2020 year | 44 cases | -8.33 % |
Trends in filing of joint patent applications with メルク・シャープ・アンド・ドーム・コーポレーション
その他の医薬技術 filed 99 joint applications with メルク・シャープ・アンド・ドーム・コーポレーション for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 10 cases in total) is 1.7, and the median is 0.5. The coefficient of variation (standard deviation/mean) is 1.2, and there have been very big fluctuations in the number of filings from year to year.
The highest number of filings in 2015 with 32 cases, and their lowest number in 2022 with 0 cases.
| Index | Value |
|---|---|
| Average | 1.7 patents |
| Std Dev | 2.1 |
| COV | 1.2 |
| Year | Cases | YOY |
|---|---|---|
| 2020 year | 1 cases | -75.0 % |
| 2019 year | 4 cases | -20.00 % |
| 2018 year | 5 cases | -58.3 % |
Information on important patents (JP)
The following shows JP patents held by その他の医薬技術 that have had an invalidation trial against them demanded or an opposition filed against them by a third party, and その他の医薬技術’s JP patents/patent applications of high importance cited by Examiners in patent examination processes.
By noting the most important patents, you can obtain knowledge of the competitive business environment in which その他の医薬技術 is placed (e.g., whether it is a fiercely competitive environment or an oligopolistic market and the like). In general, it can be understood that a company with a large number of demands for invalidation trials is developing their business in a business environment where IP disputes are common.
If you want to search for more detailed information, you can use Patent Integration to retrieve and download by company cited patents/patent applications or patents undergoing invalidation trials. You can quickly extract important patents from a patent set that includes multiple competitors by cross-referencing with other keywords and patent classifications. Please consider using it for searches for important patents/patent applications.
Glossary
- Cited
- Indicates that the patent/patent application has been cited (by Examiners) in notices of reasons for rejection in the examination process of other (Japanese, U.S., or European) patent applications. The higher the number of citations, the more important the patent/patent application is considered to be.
- Request for invalidation trial
- Indicates that a third party has requested a procedure to invalidate the patent. It is likely to affect the business of third parties and is considered to be of high importance.
- Opposition
- Indicates that a third party has filed a petition with the Patent Office to hear the validity of the patent again. Like the trial for invalidation, it is considered to be of high importance.
- Information provision
- Indicates that a third party has provided the Patent Office with useful information for examination for the patent filed. It is usually considered to be of high importance because it is done to prevent the patent from being granted.
- Browsing request
- Indicates that a third party has requested the Patent Office to view the patent bag (a set of documents exchanged between the Patent Office and the applicant). The bag is often checked prior to trial for invalidation, opposition, and provision of information, and is considered to be a highly important patent.
Invalidationed Trial cases
List of latest Invalidationed Trial patents
In the last 3 years (2021-12-01 ~ 2024-11-30), there were 23 patents Invalidation Trial from third parties. The average number of Invalidation Trial is 1.4 times. The most recently Invalidation Trial patent is 特許6995822 "ＤＰＰ ＩＶインヒビターの使用" (Invalidation Trial day 2024-06-25) , next is 特許5419866 "新たな医薬組成物" (Invalidation Trial day 2024-05-30) .
| - | No. | Title | Invalidation Trial days |
|---|---|---|---|
| 1 | 特許6995822 | ＤＰＰ ＩＶインヒビターの使用 | 2024-06-25 |
| 2 | 特許5419866 | 新たな医薬組成物 | 2024-05-30 |
| 3 | 特許6144713 | 新たな医薬組成物 | 2024-05-30 |
| 4 | 特許5735078 | 新たな医薬組成物 | 2024-05-30 |
| 5 | 特許6560289 | 新たな医薬組成物 | 2024-05-30 |
| 6 | 特許6814997 | ５’キャップ付ＲＮＡを合成するための組成物および方法 | 2024-05-15 |
| 7 | 特許7258832 | 多発性硬化症を処置するためのＳ１Ｐ受容体モジュレーター | 2024-05-08 |
| 8 | 特許6811203 | 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療 | 2024-04-24 |
| 9 | 特許6480887 | メトホルミン治療に不適切な患者における糖尿病の治療 | 2024-03-22 |
| 10 | 特許6556767 | ＤＰＰ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬 | 2024-03-19 |
Top Patents/Patent Applications with the Highest Number of Invalidationed Trial
Of the patent applications filed in the last 10 years (2014-12-01 to 2024-11-30), 22 patents/patent applications were invalidation trial more than once in the examination process of other patent applications. The mean of the number of invalidation trial is 1.3. The most invalidation trial patent is 特許6445123 "癌を治療するための方法及び組成物" (5 times) , and the next most invalidation trial patent is 特許6198346 "１回当たり１００〜２００単位のＰＴＨが週１回投与されることを特徴とする、ＰＴＨ含有骨粗鬆症治療／予防剤" (2 times) .
| - | No. | Title | |
|---|---|---|---|
| 1 | 特許6445123 | 癌を治療するための方法及び組成物 | 5 times |
| 2 | 特許6198346 | １回当たり１００〜２００単位のＰＴＨが週１回投与されることを特徴とする、ＰＴＨ含有骨粗鬆症治療／予防剤 | 2 times |
| 3 | 特許6480887 | メトホルミン治療に不適切な患者における糖尿病の治療 | 2 times |
| 4 | 特許6143809 | ＤＰＰＩＶインヒビターの使用 | 2 times |
| 5 | 特許6274634 | 骨粗鬆症治療剤ないし予防剤 | 1 times |
Oppositioned cases
List of latest Oppositioned patents
In the last 3 years (2021-12-01 ~ 2024-11-30), there were 24 patents Opposition from third parties. The average number of Opposition is 1.0 times. The most recently Opposition patent is 特許7429503 "ナットウキナーゼを含む経口組成物" (Opposition day 2024-08-08) , next is 特許7425560 "固形製剤の製造方法" (Opposition day 2024-07-22) .
| - | No. | Title | Opposition days |
|---|---|---|---|
| 1 | 特許7429503 | ナットウキナーゼを含む経口組成物 | 2024-08-08 |
| 2 | 特許7425560 | 固形製剤の製造方法 | 2024-07-22 |
| 3 | 特許7420330 | アレルギーの抗原およびそのエピトープ | 2024-07-10 |
| 4 | 特許7448953 | 眼疾患のための細胞モデル及び治療関連出願への相互参照 | 2024-04-17 |
| 5 | 特許7348543 | メッセンジャーＲＮＡのカプセル化 | 2024-02-29 |
| 6 | 特許7275044 | 慢性炎症性脱髄性多発神経炎の治療における使用のための免疫グロブリン製品 | 2023-11-17 |
| 7 | 特許7244922 | 化学修飾された一本鎖ＲＮＡ編集オリゴヌクレオチド | 2023-09-20 |
| 8 | 特許7240675 | オトフェルリンを発現させるための組成物および方法 | 2023-09-19 |
| 9 | 特許7237544 | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 | 2023-09-11 |
| 10 | 特許7223501 | 経口組成物 | 2023-08-15 |
Protested cases
List of latest Protested patents
In the last 3 years (2021-12-01 ~ 2024-11-30), there were 91 patents Protest from third parties. The average number of Protest is 1.6 times. The most recently Protest patent is 特開2023-052910 "可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩" (Protest day 2024-11-26) , next is 特開2023-005117 "抗アレルギー組成物、抗アレルギー併用剤セット、ＩＬ－９産生抑制組成物およびＮＦＡＴｃ１およびＮＦＡＴｃ２の核内移行抑制組成物" (Protest day 2024-11-21) .
| - | No. | Title | Protest days |
|---|---|---|---|
| 1 | 特開2023-052910 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 | 2024-11-26 |
| 2 | 特開2023-005117 | 抗アレルギー組成物、抗アレルギー併用剤セット、ＩＬ－９産生抑制組成物およびＮＦＡＴｃ１およびＮＦＡＴｃ２の核内移行抑制組成物 | 2024-11-21 |
| 3 | 特表2022-500417 | 咬筋肥大症の治療方法 | 2024-11-13 |
| 4 | 特表2023-514396 | 抗菌組成物 | 2024-09-27 |
| 5 | 特開2023-111768 | 錠剤、錠剤の崩壊性を改善する方法 | 2024-08-22 |
| 6 | 特表2022-546587 | 生物製剤の捕捉及び精製のための方法 | 2024-08-22 |
| 7 | 特表2022-520560 | ベータ－ヒドロキシブチレート混合塩－酸組成物および使用方法 | 2024-08-06 |
| 8 | 特開2022-070061 | 外用組成物 | 2024-07-31 |
| 9 | 特表2024-508601 | 多層経口薄フィルム | 2024-07-26 |
| 10 | 特開2024-023819 | ナットウキナーゼを含む経口組成物 | 2024-07-22 |
| 11 | 特表2022-502482 | 骨損傷を治療するための組成物及び方法 | 2024-07-19 |
| 12 | 特許7558059 | 口腔用組成物 | 2024-07-16 |
| 13 | 特開2023-168547 | 眼科組成物 | 2024-06-26 |
| 14 | 特開2021-098756 | 眼科組成物 | 2024-06-12 |
| 15 | 特表2022-506635 | オリゴ糖組成物およびその使用方法 | 2024-06-03 |
| 16 | 特開2021-014445 | ゲルインウォーター型エマルション、その製造方法及び経皮吸収剤 | 2024-05-30 |
| 17 | 特開2023-022363 | 細胞保護用剤 | 2024-04-18 |
| 18 | 特表2023-518247 | ナノ粒子の効率的な分散のための材料および方法 | 2024-04-09 |
| 19 | 特許7545478 | 環状ジペプチド、プリンヌクレオチド及び／又はアミノ酸とチキンエキスとを含む組成物、その製造方法、並びに、環状ジペプチド、プリンヌクレオチド及び／又はアミノ酸、並びにチキンエキスの使用 | 2024-03-25 |
| 20 | 特表2022-552052 | 抗ＶＥＧＦタンパク質組成物及びその製造方法 | 2024-03-12 |
Top Patents/Patent Applications with the Highest Number of Protested
Of the patent applications filed in the last 10 years (2014-12-01 to 2024-11-30), 207 patents/patent applications were protest more than once in the examination process of other patent applications. The mean of the number of protest is 1.5. The most protest patent is 特許7320919 "小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療" (10 times) , and the next most protest patent is 特開2016-193894 "生菌含有製剤" (6 times) .
| - | No. | Title | |
|---|---|---|---|
| 1 | 特許7320919 | 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 | 10 times |
| 2 | 特開2016-193894 | 生菌含有製剤 | 6 times |
| 3 | 特許7565148 | 外用組成物 | 6 times |
| 4 | 特開2017-061467 | 血管新生眼疾患を処置するためのＶＥＧＦアンタゴニストの使用 | 5 times |
| 5 | 特許6934150 | 経口組成物 | 5 times |
Inspectioned cases
List of latest Inspectioned patents
In the last 3 years (2021-12-01 ~ 2024-11-30), there were 847 patents Inspection from third parties. The average number of Inspection is 1.7 times. The most recently Inspection patent is 特表2022-547154 "調節可能な制御のためのＣＡ２－ＩＬ１５融合タンパク質" (Inspection day 2024-11-25) , next is 特表2022-516318 "カプセル化ポリヌクレオチド及び使用方法" (Inspection day 2024-11-22) .
| - | No. | Title | Inspection days |
|---|---|---|---|
| 1 | 特表2022-547154 | 調節可能な制御のためのＣＡ２－ＩＬ１５融合タンパク質 | 2024-11-25 |
| 2 | 特表2022-516318 | カプセル化ポリヌクレオチド及び使用方法 | 2024-11-22 |
| 3 | 特表2022-516199 | ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物 | 2024-11-21 |
| 4 | 特表2022-514116 | 新規な癌抗原及び方法 | 2024-11-21 |
| 5 | 特表2021-530478 | ＮａＶ１．８を阻害するためのピリジンカルボキシアミド化合物 | 2024-11-18 |
| 6 | 特表2022-500417 | 咬筋肥大症の治療方法 | 2024-11-18 |
| 7 | 特許6231007 | ＢＣＭＡおよびＣＤ３に対する結合分子 | 2024-11-15 |
| 8 | 特許7194240 | 抗ＢＣＭＡ抗体、ＢＣＭＡ及びＣＤ３に結合する二重特異性抗原結合分子、並びにそれらの使用 | 2024-11-15 |
| 9 | 特開2023-027228 | 抗ＢＣＭＡ抗体、ＢＣＭＡ及びＣＤ３に結合する二重特異性抗原結合分子、並びにそれらの使用 | 2024-11-15 |
| 10 | 特表2018-525005 | 抗ＢＣＭＡ抗体、ＢＣＭＡ及びＣＤ３に結合する二重特異性抗原結合分子、並びにそれらの使用 | 2024-11-15 |
| 11 | 特開2022-097486 | ｍＲＮＡの機能状態を変化させてその選択的かつ特異的な認識を可能にする方法 | 2024-11-14 |
| 12 | 特表2022-518223 | 不妊治療成功の予測のための子宮内膜液 | 2024-11-13 |
| 13 | 特開2022-140622 | 器官の生存率を改善する方法 | 2024-11-13 |
| 14 | 特表2022-513077 | クロストリジウム・ディフィシル多成分ワクチン | 2024-11-12 |
| 15 | 特許5208113 | 特定のエンドセリン受容体アンタゴニストとＰＤＥ５阻害剤を含む治療用組成物 | 2024-11-08 |
| 16 | 特開2022-137094 | グルタチオンを標的に送達するための化合物ならびにその製造方法および使用方法 | 2024-11-07 |
| 17 | 特表2022-545835 | 甲状腺眼症の治療方法 | 2024-11-07 |
| 18 | 特表2023-504773 | 眼遺伝子送達のためのＡＡＶベクター変異体 | 2024-11-07 |
| 19 | 特表2024-534353 | ヌクレオチド配列合成関連メトリックを生成するためのシステム及び方法 | 2024-11-06 |
| 20 | 特表2024-512769 | 抗原特異的Ｔ細胞を生成し、疾患を治療するための材料及び方法 | 2024-11-06 |
Top Patents/Patent Applications with the Highest Number of Inspectioned
Of the patent applications filed in the last 10 years (2014-12-01 to 2024-11-30), 1,507 patents/patent applications were inspection more than once in the examination process of other patent applications. The mean of the number of inspection is 1.3. The most inspection patent is 特開2017-214435 "抗ＣＤ２０抗体の投与を含むＢ細胞リンパ腫の併用療法" (43 times) , and the next most inspection patent is 特許7320919 "小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療" (20 times) .
| - | No. | Title | |
|---|---|---|---|
| 1 | 特開2017-214435 | 抗ＣＤ２０抗体の投与を含むＢ細胞リンパ腫の併用療法 | 43 times |
| 2 | 特許7320919 | 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 | 20 times |
| 3 | 特許6198346 | １回当たり１００〜２００単位のＰＴＨが週１回投与されることを特徴とする、ＰＴＨ含有骨粗鬆症治療／予防剤 | 18 times |
| 4 | 特許6150846 | １回当たり１００〜２００単位のＰＴＨが週１回投与されることを特徴とする、ＰＴＨ含有骨粗鬆症治療／予防剤 | 15 times |
| 5 | 特許6025881 | 高純度ＰＴＨ含有凍結乾燥製剤およびその製造方法 | 13 times |
Cited cases
Top Patents/Patent Applications with the Highest Number of Cited
Of the patent applications filed in the last 10 years (2014-12-01 to 2024-11-30), 6,074 patents/patent applications were cited more than once in the examination process of other patent applications. The mean of the number of cited is 2.1. The most cited patent is 特許6785819 "ＫＲＡＳ Ｇ１２Ｃ阻害剤及びその使用方法" (34 times) , and the next most cited patent is 特許6778114 "イミド系タンパク質分解モジュレーター及び関連する使用方法" (34 times) .
| - | No. | Title | |
|---|---|---|---|
| 1 | 特許6785819 | ＫＲＡＳ Ｇ１２Ｃ阻害剤及びその使用方法 | 34 times |
| 2 | 特許6778114 | イミド系タンパク質分解モジュレーター及び関連する使用方法 | 34 times |
| 3 | 特許6400738 | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 | 33 times |
| 4 | 特表2017-500035 | 遺伝子編集用のＣＡＳ多様体 | 29 times |
| 5 | 特許6688352 | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 | 29 times |
Providing patent information to the media (newspapers, magazines, etc.)
"Patent Integration Report" is a web service provided by "Patent Integration Co., Ltd." operated by patent attorneys who are experts in intellectual property rights. Based on the latest patent data, this is one of the largest patent report services in Japan that provides information on technology trends in various companies and technology fields.
The purpose of this web service is to make intellectual property information familiar to many people, regardless of whether they have an interest in intellectual property rights, and to make use of it.
We actively provide various types of patent information that can be used in various media articles such as newspapers, magazines, and web media. Please feel free to contact us from "Inquiry form for details on the content of patent information that can be provided, conditions for provision, etc. Please contact us.
About this Site
All rights related to the data, documents and charts belong to "an integrated patent search/analysis service provider, Patent Integration". Please specify the source “Patent Integration Report, URL: https://patent-i.com/report/en/" when inserting them into in-house materials, external report materials, etc., regardless of whether they are paid or free of charge.
Patent data is obtained by aggregating and analyzing the latest patent data issued by the Patent Offices of respective countries and jurisdictions and by WIPO. Although we take great care in publishing and analyzing the results, we do not guarantee the correctness of the data. We appreciate your understanding.
If you have any concerns about this service, please feel free to contact us.
All rights to the data, documents, figures and tables are reserved by e-Patent. When publishing internal documents, external reports, etc. (whether paid or free of charge), please use the following URL: https://e-patent.co.jp/.
Please note the following points for use.
e-Patent will not be liable for any damages or losses arising from the use of the global patent application status, ranking information, or population search formula in the "SDGs Global Company Ranking from a Patent Perspective". Items with ● in front of the target are not supported at this time (judged to be difficult to approach from the patent information analysis).
Citation of patent application status and ranking information
There is no problem to cite patent application status and ranking information, but please clearly indicate "Source: e-Patent Co.
Graphs are image data.
Please note that the various graphs are image data, but we cannot provide them in text data.Scope of coverage for each goal/target
- Based on the description of each goal and target of the SDGs, we have set the scope of technologies to be covered based on our and e-Patent's past experience, etc. (in some cases, the search is based on social issues themselves). Therefore, please note that there is a possibility that this "SDGs Global Company Ranking from Patent Perspective" may not cover 100%.
- A population search formula is clearly indicated for each goal/target (database: Patent Integration). You may use the population search formula as it is, or you may improve it by yourself.
- This search covers patents and utility models, including both published and registered patents (design and design patents are excluded). The unit of count is the number of applications, not the number of patent families.
About the name collation and name control of applicants and right holders
- Company rankings are based on the results calculated by "Patent Integration", with Japanese organizations in Japanese and other companies in English (some are in Japanese).
- Company names may be the names of the companies at the time of application, but the results calculated by Patent Integration are used as is. Company names are used as they were at the time of application.
- Because of the fluctuation in the names of companies (i.e., applicant/right holder names in the patent information), there are cases where the same company appears more than once in the top 10. The number of applications filed by the same company in the top 10 is the total number of applications filed by the company.
Credit notation
・MeCab user dictionary for science technology term © National Bioscience Database Center licensed under CC Attribution-Share Alike 4.0 International
Our Commitment to Safety and Security
Patent Integration Co., Ltd. is committed to providing high-quality patent information based on the latest patent data on more than 45 million cases collected from the Patent Offices in Japan, the U.S., Europe, and Taiwan and from PCT publication. 
Patent Integration Co., Ltd. collects the patent data from the Patent Offices in Japan, the U.S., Europe, and Taiwan and from PCT publications to provide it widely in the form of reports so that anyone can check patent information and patent trends with confidence. 
Patent Integration Co., Ltd. is committed to various efforts to enhance the reliability of the information and to allow users to search patent information with confidence.